Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients.
Emily WangAnna S JanVi P DoanJill B FergusonJason C YehPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2018)
Despite current strategies, refractory or recurrent cytomegalovirus infection and disease remain a clinical challenge to treat in the stem cell transplant patient population. Leflunomide used in combination with other concomitant therapies use for refractory cytomegalovirus infection in clinical practice may be a safe and effective option in the allogeneic stem cell transplant patient population.